An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development

Abstract

This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12 AEDs in clinical trials (Phases I - III) are compared: ADCI, AWD 131-138, DP-VPA, ganaxolone, levetiracetam, losigamone, pregabalin, remacemide hydrochloride, retigabine, rufinamide, soretolide and TV1901. One of these, levetiracetam has been approved in the USA and is waiting approval in other countries. The protective index of rufinamide, as shown in rodent models of epilepsy, is much higher than that of most common AEDs. Features which make it a desirable AED are: (i) a broad spectrum of anti-epileptic actions including both partial and symptomatic generalised epilepsy; (ii) a statistically significant reduction in seizure frequency in clinical trials; (iii) efficacy and safety shown in a broad range of age groups including children and the elderly; (iv) rapid oral absorption enabling quick titration to effective dose and (v) a benign adverse event profile. Most of the events did not lead to discontinuation in clinical trials. These features offer considerable advantages over the existing anti-epileptic drugs. It is one of the two drugs in development which have reached Phase III and is expected to be approved by the year 2001 - 2002.

• anti-epileptic drugs
• AWD 131-138
• clinical trials
• drug development
• epilepsy
• felbamate
• fosphenytoin
• gabapentin
• ganaxolone
• gene therapy
• lamotrigine
• levetiracetam
• losigamone
• neurocybernetic prosthesis
• oxcarbazepine
• pregabalin
• remacemide hydrochloride
• retigabine
• rufinamide
• soretolide
• status epilepticus
• tiagabine
• topiramate
• TV1901
• valproic acid
• vigabatrin
• zonisamide